Regeneron reports strong third quarter revenue

Regeneron has reported third quarter revenue of $1.2 billion for 2016, up 7% from the same quarter last year.

Sales of Eylea (aflibercept) contributed substantially to the earnings, as the blockbuster drug brought in $857 million, an increase from $738 million in 2015.

The company’s research and development costs rose from $426 million to $543 million, part of which was attributed to a $25 million upfront payment for a 5-year licensing and collaboration agreement with Adicet to develop a pipeline of engineered immune-cell therapeutics.